ARS Pharmaceuticals Hits New 52-Week Low at $8.59 Amid Financial Struggles

ARS Pharmaceuticals, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 8.59 on October 30, 2025. This decline marks a significant downturn for the company, which has seen its stock price drop by 4.96% over the past year, contrasting sharply with the S&P 500's performance of 18.13% during the same period.
The company has faced challenges recently, reporting negative results in March 2025 after three consecutive quarters of positive performance. Key financial metrics indicate a difficult landscape, with a return on equity of -24.97% and a debt-to-equity ratio of -1.25. Additionally, the company's operating profit for the quarter was recorded at USD -47.33 million, reflecting ongoing financial pressures.

Despite a historical high of USD 18.90, ARS Pharmaceuticals has struggled to maintain its market position, with a notable decline in stock performance over the last year. The company's price-to-book ratio stands at 5.50, further illustrating the challenges it faces in the current market environment.